Physician profile
Mohinder Vindhyal
NPI 1205198967
$4,466.04
in general payments reported to CMS, 2019-2025
14 companies · $1,822 in 2025
The $1,822 reported for 2025 was more than what 97% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.58 · 2021: $241 · 2022: $195 · 2023: $358 · 2024: $1,827 · 2025: $1,822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,712 · Travel and Lodging: $687 · Education: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,711.71 |
| Travel and Lodging | $687.06 |
| Education | $608.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $1,192.79 | 2024-2025 | Gore Cardioform Asd Occluder, Gore Cardioform Septal Occluder |
| Medtronic, INC. | $746.75 | 2021-2025 | Symplicity G3, Onyx Frontier, Resolute Onyx |
| Abbott Laboratories | $543.18 | 2021-2025 | Optis, Perclose Prostyle, Thoratec Heartmate 3 Lvas Implant Kit |
| Boston Scientific Corporation | $542.65 | 2024 | |
| Shockwave Medical, INC | $355.16 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $331.09 | 2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $276.13 | 2019-2025 | Lifevest |
| Penumbra, INC. | $162.53 | 2024 | Indigo System, Ruby Coil |
| Philips North America LLC | $114.66 | 2023 | |
| Chiesi USA, INC. | $101.63 | 2024 | Kengreal |
| Edwards Lifesciences Corporation | $42.56 | 2024 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $19.58 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $18.79 | 2025 | Capvaxive, Verquvo |
| Esperion Therapeutics, INC. | $18.54 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohinder Vindhyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.